Status:
UNKNOWN
Cardiovascular Complications of Carfilzomib
Lead Sponsor:
European Georges Pompidou Hospital
Conditions:
Myeloma
Heart Failure
Eligibility:
All Genders
18+ years
Brief Summary
Cardiovascular toxicity of carfilzomib, a last generation proteasome inhibitor, is highly incident according to retrospective data. Prospective cohort study of patients initiated on carfilzomib.
Eligibility Criteria
Inclusion
- Intention to treat by Carfilzomib
Exclusion
- History of carfilzomib treatment
Key Trial Info
Start Date :
May 21 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
May 21 2022
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT04407858
Start Date
May 21 2020
End Date
May 21 2022
Last Update
June 9 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Assistance Publique Hôpitaux de Paris - Centre Université de Paris
Paris, France, 75015